Role of membrane mechanisms (omega-3 fatty acids and connexin-43) in pathology of cardiovascular disease

Coordinator: Narcisa Tribulová

Number of project: MAD-SK-Ukrajine

Date: 1.1.2008 – 31.12.2013

Cooperating country: Ukraina


In agreement with the concept of health care in the field cardiology the specific goal of the project is to provide further evidence supporting the role of omega-3 fatty acids in primary and secondary prevention of cardiovascular diseases that are major causes of morbidity and mortality worldwide. There are several goals of the projects: 1) To elaborate and introduce the method for the assay of a new risk factor of cardiovascular diseases, omega-3 index, and to monitor its changes in relationship to injury of the heart and its vulnerability to lethal arrhythmias in experimental rat models characterized by hypertriglyceridemia, hypertension, diabetes, ischemia;  2) To monitor omega-3 index in humans suffering from another risk factors such as overweight, dyslipidemia, hypertension, insulin resistance while focusing on impact of age (children and adolescent versus older individuals) and gender in Slovak and Ukraine population; 3) To reveal a new cellular and molecular mechanisms involved in omega-3 fatty acids protection against cardiac injury and malignant arrhythmias by using laboratory equipments and methodological potential of both institutions. In this context the investigation will focus on the effects of omega-3 fatty acids on cell-to-cell communication ensured by intercellular connexin channels and intracellular signalling mediated by protein kinases and NO as well as on the effect of omega-3 fatty acids on target proteins gene expression via nuclear PPAR receptors; 4) To prepare findings for publications in CC journals as well as for presentations on cardiological and other congresses to support by this way the impact of diet-therapy; 5) To elaborate project proposal for the possibility to participate in international research programmes. There is an assumption that results will be used in „the evidence based medicine“, in the screening of individuals with a risk of cardiovascular diseases as well as in the prevention of sudden cardiac death.